1. Home
  2. MKTW vs MREO Comparison

MKTW vs MREO Comparison

Compare MKTW & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MarketWise Inc.

MKTW

MarketWise Inc.

SELL

Current Price

$20.50

Market Cap

55.9M

Sector

Technology

ML Signal

SELL

Logo Mereo BioPharma Group plc

MREO

Mereo BioPharma Group plc

SELL

Current Price

$0.28

Market Cap

50.3M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
MKTW
MREO
Founded
1999
2015
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
55.9M
50.3M
IPO Year
2020
2017

Fundamental Metrics

Financial Performance
Metric
MKTW
MREO
Price
$20.50
$0.28
Analyst Decision
Buy
Analyst Count
0
8
Target Price
★ $23.76
$1.96
AVG Volume (30 Days)
15.3K
★ 655.7K
Earning Date
11-05-2026
11-09-2026
Dividend Yield
★ 8.50%
N/A
EPS Growth
★ 1183.33
16.67
EPS
★ 0.12
N/A
Revenue
★ $512,403,000.00
$500,000.00
Revenue This Year
N/A
$59.51
Revenue Next Year
$9.24
$2,326.81
P/E Ratio
$170.01
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$13.49
$0.20
52 Week High
$23.00
$2.37

Technical Indicators

Market Signals
Indicator
MKTW
MREO
Relative Strength Index (RSI) 49.12 40.40
Support Level $19.19 $0.27
Resistance Level $21.05 $0.35
Average True Range (ATR) 0.84 0.02
MACD -0.10 0.00
Stochastic Oscillator 24.87 20.70

Price Performance

Historical Comparison
MKTW
MREO

About MKTW MarketWise Inc.

Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas, and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms, including mobile, desktop, and tablets.

About MREO Mereo BioPharma Group plc

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Share on Social Networks: